Search results for: Health Policy and Regulation

Cornerstones of ‘Fair’ Drug Coverage

30 September 2020

…and clinical societies joined ICER’s Policy Leadership Forum – senior policy leaders from 25 payers and life science companies – in December 2019 to discuss a preliminary draft of this…

Terms and Conditions

…interest in and to the site and all of the content, software, code, data and other materials therein, and the look-and-feel, design and organisation of any aspect thereof, including any…

New Study of Time Lags in Translating Medical Research into Practice

30 November 2012

One of the greatest challenges in biomedical and health research is ensuring that research findings are translated effectively and without undue delay from ‘bench to bedside’. As previous analysis has…

Interdependencies in Funding Medical Research in the UK

2 July 2014

…by those interviewed. The study found that economies of scale are relatively modest except when research requires particularly specialized and costly equipment and infrastructure. 2. Analysis of the interdependencies and…

Government and Charity Funding of Cancer Research: Public Preferences and Choices

13 October 2015

…as an OHE Research Paper. Reference: Shah, K.K., Sussex, J. and Hernandez-Villafuerte, K., 2015. Government and charity funding of cancer research: public preferences and choices. Health Research Policy and Systems,…

OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?

10 January 2019

…and Júlia González Esquerré work in the NHS Improvement Economics Team, which provides economics expertise to NHS Improvement (previously Monitor and the Trust Development Authority) and the provider sector. Their…

Costs of Mental Care

7 January 1965

Expenditure by the National Health Service in England and Wales on patients suffering mental disorders currently exceeds £130m. a year, about one-eighth of the total health services’ expenditure. This large…

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

1 November 2009

This study compares pricing and reimbursement (P&R) policy for 43 orphan medicinal products (OMPs) across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden and the UK. Examined…

European Medicines Pricing and Reimbursement: Now and the Future

1 January 2007

…and reimbursement policies in Germany: current and future trends; Pricing and reimbursement policies in UK: a current and future trends; Pricing and reimbursement policies in Italy: current and future trends;…